Benfotiamine
9 benefits mapped to clinical evidence across supplements.
Dose per serving from products
433 products in our catalogue print how much Benfotiamine a serving holds.
Most common: 250 mg to 500 mg, 29% of 433 products.
| Dose per serving | Products |
|---|---|
| 500 mcg or less | 17 |
| 500 mcg to 1 mg | 10 |
| 1 mg to 2.5 mg | 7 |
| 2.5 mg to 5 mg | 10 |
| 5 mg to 10 mg | 12 |
| 10 mg to 25 mg | 52 |
| 25 mg to 50 mg | 42 |
| 50 mg to 100 mg | 33 |
| 100 mg to 250 mg | 87 |
| 250 mg to 500 mg | 126 |
| 500 mg to 1 g | 37 |
Dose per serving from research
20 study groups in 11 studies say how much Benfotiamine participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 500 mg to 1 g, 35% of 20 study groups.
| Daily dose | Study groups |
|---|---|
| 50 mg to 100 mg | 2 |
| 100 mg to 250 mg | 5 |
| 250 mg to 500 mg | 4 |
| 500 mg to 1 g | 7 |
| 1 g to 2.5 g | 2 |
Benefit Evidence
Research sources
Nerve health (5)
- Benfotiamine in the treatment of diabetic polyneuropathy--a three-week randomized, controlled pilot study (BEDIP study)
PubMed ID: 15726875
3-week double-blind pilot in diabetic neuropathy reduced neuropathy scores and pain vs placebo — clear symptomatic peripheral nerve comfort evidence.
- Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study
PubMed ID: 18473286
6-week DPN trial showed symptom (especially pain) improvement vs placebo, particularly at higher dose — strong symptomatic benefit.
- Benfotiamine in treatment of alcoholic polyneuropathy: an 8-week randomized controlled study (BAP I Study)
PubMed ID: 9872352
8-week RCT in alcoholic polyneuropathy showed significant improvements in vibration sense, motor function and neuropathy score — strong clinical evidence.
- Therapeutic efficacy of "Milgamma" in patients with painful diabetic neuropathy
PubMed ID: 9575643
Milgamma (benfotiamine+B12) reduced neuropathic pain and improved vibration sense over 3 months — symptomatic benefit though product combined.
- Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy
PubMed ID: 10219465
6-week randomized trial in diabetic neuropathy showed dose-dependent larger improvements in pain and sensory measures with higher benfotiamine doses.
Brain health (2)
- Change in psychiatric symptomatology after benfotiamine treatment in males is related to lifetime alcoholism severity
PubMed ID: 25908323
In alcohol-dependent men benfotiamine raised thiamine and selectively reduced some psychiatric symptom subscales in a high-severity subgroup — moderate cognitive/psychiatric relevance.
- Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial
PubMed ID: 33074237
12-month RCT in amyloid-positive MCI/mild AD showed less cognitive and functional decline and lower AGE rise — direct clinical signal for brain function.
Blood sugar (2)
- Efficacy and tolerability of advanced glycation end-products inhibitor in osteoarthritis: a randomized, double-blind, placebo-controlled study
PubMed ID: 23354008
Combination AGE-inhibitor lowered serum AGEs significantly over 24 weeks (multicomponent intervention).
- Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial
PubMed ID: 33074237
In MCI/mild AD RCT benfotiamine inhibited AGE rise over 12 months — direct human evidence for reducing sugar-related molecular damage.
Energy & Fatigue (1)
- Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of Benfotiamine in Healthy Subjects
PubMed ID: 33727798
Phase I single/multiple-dose PK: dose-dependent increases in thiamine metabolites and TDP accumulation — confirms cellular delivery in humans.
Mood balance (1)
- Change in psychiatric symptomatology after benfotiamine treatment in males is related to lifetime alcoholism severity
PubMed ID: 25908323
In alcohol-dependent men benfotiamine raised thiamine and selectively reduced obsessive-compulsive and phobic anxiety scores in high-severity subgroup — clinically relevant mood/psychiatric improvements.
Detoxification (1)
- A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy
PubMed ID: 20413516
In T2D with albuminuria benfotiamine raised thiamine and transketolase activity but did not change albuminuria or tubular markers over 12 weeks — biochemical benefit but no short-term kidney outcome effect.
Antioxidant (1)
- Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial
PubMed ID: 33074237
MCI trial showed inhibition of AGE rise (AGEs linked to oxidative stress) and less cognitive decline — indirect oxidative-stress-related benefit.
Healthy aging (1)
- Benfotiamine and Cognitive Decline in Alzheimer's Disease: Results of a Randomized Placebo-Controlled Phase IIa Clinical Trial
PubMed ID: 33074237
12-month RCT in amyloid-positive MCI/mild AD showed less cognitive/functional decline and inhibited AGE rise — relevant to aging processes.
Inflammation (1)
- Efficacy and tolerability of advanced glycation end-products inhibitor in osteoarthritis: a randomized, double-blind, placebo-controlled study
PubMed ID: 23354008
Combination AGE-inhibitor (including benfotiamine) reduced CRP and serum AGEs in OA patients — meaningful anti-inflammatory biomarker response, though attribution is shared.
Similar by evidence
Supplements the same benefits carry qualifying findings for — a fact about the evidence graph, not a recommendation to swap.
Products with Benfotiamine
Search all556 products whose verified label declares Benfotiamine — not every bottle that mentions it in a title.
Being studied right now
Recruiting clinical trials registered on ClinicalTrials.gov. A trial in progress has no result yet — this is what the field is asking, not what it found.